Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma
These findings suggest that in the current clinical landscape, EV might be a more preferable option than Pl-CT rechallenge subsequent to avelumab maintenance therapy, thereby influencing treatment decisions for metastatic urothelial carcinoma.
Authors
- Yosuke Morizawa (ORCID: https://orcid.org/0000-0001-7142-5901)
- Kuniaki Inoue (ORCID: https://orcid.org/0000-0002-4066-9951)
- Mitsuru Tomizawa (ORCID: https://orcid.org/0000-0002-9065-7828)
- Kiyohide Fujimoto (ORCID: https://orcid.org/0000-0003-1507-2464)
- Keichi Sakamoto
- Makito Miyake (ORCID: https://orcid.org/0000-0001-9503-7356)
- Mikiko Onishi
- Kenta Onishi (ORCID: https://orcid.org/0000-0001-5716-5904)
- Shunta Hori (ORCID: https://orcid.org/0000-0001-9514-9964)
- Yasushi Nakai (ORCID: https://orcid.org/0000-0002-7579-0372)
- Takanosuke Yoshikawa
- Daisuke Gotoh (ORCID: https://orcid.org/0000-0002-6056-3820)
- Takuto Shimizu (ORCID: https://orcid.org/0000-0002-6403-7959)
- Nobumichi Tanaka (ORCID: https://orcid.org/0000-0001-9242-7877)
- Nobutaka Nishimura
- Fumisato Maesaka (ORCID: https://orcid.org/0000-0001-7754-7184)
- Kosuke Mieda
- Akira Tachibana (ORCID: https://orcid.org/0000-0001-5995-937X)
- Norimi Takamatsu
Institutions
- Osaka Kaisei Hospital (JP)
- Hoshigaoka Medical Center (JP)
- Osaka Ekisaikai Hospital (JP)
- Nara City Hospital (JP)
- Yamato Municipal Hospital (JP)
- Nara Prefecture General Medical Center (JP)
- Nara Medical University (JP)
Publication Details
- Journal
- Bladder Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/23523735251317423
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01